middle.news
How Actinogen’s $13.8m Funding Boost Could Accelerate Alzheimer’s Breakthrough
9:21am on Monday 30th of June, 2025 AEST
•
Biotechnology
Read Story
How Actinogen’s $13.8m Funding Boost Could Accelerate Alzheimer’s Breakthrough
9:21am on Monday 30th of June, 2025 AEST
Key Points
Initial $3.0m tranche received from Endpoints Capital
Conditional further $2.9m and $7.9m tranches linked to FY25 and FY26 R&D tax incentives
Funding supports XanaMIA Phase 2b/3 Alzheimer’s trial and working capital
Cash runway extended to mid-2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Actinogen Medical (ASX:ACW)
OPEN ARTICLE